Fig. 5: circPSD3 as a Sponge of miR-338-5p.

A RIP using an anti-IgG antibody or anti-HA antibody followed by RT-qPCR revealed the binding between circPSD3 and AGO2 in TPC-1 and 8305 C. B Venn diagram representing the potential binding miRNAs of circPSD3 and SUCLG2 predicted by a bioinformatics website. RNA pull-down assay using a circPSD3 probe followed by RT-qPCR revealed the binding between circPSD3 and miR-338-5p in TPC-1 (C) and 8305 C (D). RNA pull-down assay using a miR-338-5p probe followed by RT-qPCR confirmed the binding between circPSD3 and miR-338-5p in TPC-1 (E) and 8305 C (F). G Schematic diagram illustrating the motif of miR-338-5p as a link between circPSD3 and SUCLG2. H The dual-luciferase assay reports the interaction between miR-338-5p and SUCLG2 mRNA 3ʹUTR motif. I Western blotting showed that SUCLG2 downregulation induced by circPSD3 knockdown was reversed by co-treatment with a miR-338-5p inhibitor. J, K Flow cytometry and statistical results demonstrated that overexpression of SUCLG2 rescued the decreased MMP caused by circPSD3 knockdown in TPC-1. L, M Representative EdU fluorescence images and statistical results demonstrated the inhibitory effect on proliferation of circPSD3-knockdown was rescued by SUCLG2 overexpression in TPC-1. The experiments were repeated 3 times independently. Data are presented as the mean ± S.D. miR-NC miRNA inhibitor negative control, miR-I hsa-miR-338-5p inhibitor, NC negative control group, sh sh-circPSD3 group. *P < 0.05; **P < 0.01; ***P < 0.001.